BMO Capital Reaffirms Their Hold Rating on Endo International

Gladys Abbott
August 12, 2017

Guggenheim assumed coverage on Endo International PLC in a report on Saturday, June 17th. Finally, BMO Capital Markets reissued a "hold" rating and issued a $15.00 target price on shares of Endo International PLC in a research report on Monday, May 1st.

Stock analysts at Oppenheimer Holdings upped their FY2020 EPS estimates for Endo International PLC in a research report issued to clients and investors on Tuesday.

On August 10 Morgan Stanley maintained a stock rating of "Buy" and moved down the price target from $85.00 to $13.00. On June 9 the company was changed to a "Hold" according to a Stifel Nicolaus report down from the previous "Buy" rating. The stock has a consensus rating of "Hold" and a consensus target price of $14.86. Oppenheimer Holdings analyst D. Archila now anticipates that the company will post earnings per share of $3.67 for the year, up from their prior estimate of $3.49.

Several blemishing value in the stock market possibly will oblige dedication of a person and lot of hard work. Company shares last traded at $7.47 well below $11.04, the 50 day moving average and which is well below the 200 day moving average of $11.59.

More news: Philippe Coutinho hands in Liverpool transfer request after Barcelona bids

Endo International PLC (NASDAQ:ENDP) opened at 7.55 on Friday. Finally, Mizuho reiterated a "buy" rating and issued a $19.00 price target on shares of Endo International PLC in a report on Thursday. The company had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. Endo International PLC's revenue was down 4.9% on a year-over-year basis. Analysts expect next quarter's EPS to be $0.75 with next year's EPS projected to be $3.12. As per WSJ analytic report, ENDP for the Q3 this year, the current consensus earnings per share trend estimates was $0.76, while for one month ago estimates was $0.80. If you are accessing this article on another website, it was illegally copied and republished in violation of USA and global copyright and trademark law. The legal version of this article can be read at https://theolympiareport.com/2017/08/11/endo-international-plc-nasdaqendp-cut-to-strong-sell-at-bidaskclub.html.

Teachers Advisors LLC boosted its stake in shares of Endo International PLC by 1.9% in the second quarter. The stock was purchased at an average price of $7.70 per share, for a total transaction of $154,000.00.

Moving ahead and check, how analysts are seeing this stock in term of rating and estimates. Its book value per share for the most recent quarter is $9.81 while its price to book ratio for the same period is 0.77, as for as the company's cash per share for the most recent quarter is $0, however its price to cash per share ratio for the same period is 0.

Hedge funds have recently made changes to their positions in the company. HL Financial Services LLC boosted its position in shares of Endo International PLC by 1.0% in the second quarter. Arizona State Retirement System now owns 83,700 shares of the company's stock worth $935,000 after buying an additional 1,200 shares during the period. The value of the total investment in Endo International plc - Ordina increased from $3,459,000 to $4,339,000 a change of 25.4% for the reporting period. Following the completion of the transaction, the chief operating officer now owns 181,369 shares of the company's stock, valued at approximately $1,396,541.30. OppenheimerFunds Inc. boosted its stake in shares of Endo International PLC by 182.9% in the first quarter. Macquarie Group Ltd. now owns 6,500 shares of the company's stock worth $107,000 after buying an additional 3,700 shares during the last quarter. American International Group Inc grew its investment by buying 9,673 shares an increase of 2.4%. Insiders own 0.50% of the company's stock. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX.

Other reports by LeisureTravelAid

Discuss This Article

FOLLOW OUR NEWSPAPER